Target genes of differential ACRs of BCR::ABL1\BCR::ABL1-like subtype were significantly correlated with Imatinib (p = 0.0047, Fisher’s exact test) and Dasatinib (p = 0.0178, Fisher’s exact test) (Fig. 4f), both of which are tyrosine kinase inhibitors used in BCR::ABL1\BCR::ABL1-like B-ALL treatment, whereas a significant association with Doxorubicin was observed for the ETV6::RUNX1 subtype (p = 0.0167, Fisher’s exact test) (Fig. 4f). This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.